News

2 July 2018

Leti Memory Workshop - Grenoble - France

Leti Carnot Institute organize Memory Workshop on eNVM, July 2nd 2018 - Grenoble - France.
This one-day workshop will explore short-term and long-term memory solutions. Industrials and experts will share their views, discuss start-up creation and introduce disruptive concepts that will soon penetrate the market. To expand our horizons, world-class academics will also provide their views on non-conventional applications.

More information

2 July 2018

Curie Cancer Carnot Institute names Intel lead partner to implement high performance computing and artificial intelligence in accelerating genome sequencing and interpretation for oncology

Curie Cancer Carnot Institute and Intel initiate a pioneering collaboration to develop, use and implement innovative Bioinformatics tools, pipelines and techniques to improve the use of molecular profiling across both research and clinical oncology settings.

Read the press release

19 April 2018

Leti Innovation Days - Grenoble - France

Leti Innovation Days 2018 on July 4-5th will include a series of keynotes and panel sessions from industry leaders and academics. Along the conference, a special exhibition will be open in the afternoons, and will gather microelectronics industrials and successful start-ups. 

This year, there will be 7 satellite workshops on various technical fields :

  • Design for 3D
  • Lithography
  • Quantum
  • Silicon photonics
  • Memory
  • 5 G
  • MEMS & sensors 

More information

 

 

 

19 April 2018

Curie Cancer Carnot Institute and Freenome announce a strategic collaboration in cell-free DNA analysis using machine learning technology

Curie Cancer Carnot Institute and Freenome announce a strategic collaboration to evaluate Freenome’s artificial intelligence (AI) genomics platform as a novel tool to predict patient response to immuno-oncology therapies by observing changes in circulating cell-free biomarkers.

Read more
Close

Curie Cancer Carnot Institute and Freenome announce a strategic collaboration in cell-free DNA analysis using machine learning technology

Curie Cancer Carnot Institute and Freenome announce a strategic collaboration to evaluate Freenome’s artificial intelligence (AI) genomics platform as a novel tool to predict patient response to immuno-oncology therapies by observing changes in circulating cell-free biomarkers.

In recent years so-called liquid biopsies have established the possibility of detecting circulating fragments of tumor DNA (ctDNA) and circulating tumor cells (CTCs) in the blood of patients with cancer. Institut Curie has been a pioneer in the field since the late 90’s with the first program on disseminated tumor cell (DTC) detection in the bone marrow of patients with early breast cancer. Since then, Institut Curie’s Circulating Tumor Biomarkers Laboratory has developed numerous innovative ctDNA techniques (ddPCR and NGS-based techniques).

Meanwhile, Freenome’s breakthrough use of machine learning looks beyond tumor DNA and processes the full range of cell-free (cf) biomarkers in the blood. By assembling an ever-expanding library of cell-free disease signatures, Freenome is developing a range of non-invasive blood tests for the early detection of cancer and early prediction of response to various oncology therapies. As a first step in this collaboration with Institut Curie, Freenome will analyze samples from the Analysis of Circulating Tumor Markers in the Blood (ALCINA) Trial, an umbrella trial allowing assessment of different circulating biomarkers and their correlation with clinical and pathological characteristics pertaining to response to PD-1 inhibitors alone and in combination with other therapies.

More information

19 April 2018
20 March 2018

The CALYM Carnot Institute and the Institut Roche, Partners to Accelerate Together Research against Lymphoma!

At the end of December 2017, a framework contract was signed between CALYM and the Institut Roche to define the terms of a joint call for projects for the development of preclinical and translational research partnerships in onco-hematology.

Read more
Close

The CALYM Carnot Institute and the Institut Roche, Partners to Accelerate Together Research against Lymphoma!

At the end of December 2017, a framework contract was signed between CALYM and the Institut Roche to define the terms of a joint call for projects for the development of preclinical and translational research partnerships in onco-hematology.

The CALYM Carnot institute aims at accelerating innovation and its transfer in the lymphoma field, particularly in the translational phase. To transform its discoveries of basic research into clinical applications for the patient, the institute benefits from the financial support of the French government (National Research Agency) andrelies on public-private partnerships it develops with industry and other research and technological organizations.

It is in this context that CALYM has come closer to the Institut Roche which missions are to lead and develop strategic projects of basic or translational research in partnership with the French research teams of excellence.

More information

20 March 2018
10 October 2017

CALYM again ISO9001 certified

The Carnot Insitute CALYM obtained the renewal of its ISO 9001 certification for the management and monitoring of its research activities and the coordination of its CeVi collection of lymphoma viable cells. Particularity of this year, the changeover to the 2015 version.

Read more
Close

CALYM again ISO9001 certified

The Carnot Insitute CALYM obtained the renewal of its ISO 9001 certification for the management and monitoring of its research activities and the coordination of its CeVi collection of lymphoma viable cells. Particularity of this year, the changeover to the 2015 version, following its last quality audits in September in Toulouse, Paris and Lyon.

In November 2014, CALYM obtained the ISO 9001v2008 certification for the management and monitoring of its research activities. Delivered by the certification body Euro-Quality System, this certification is multi-site, being valid for the main coordinating site (CALYM's operational team) and for each entity of the institute (excluding LYSA). It reflects the strong commitment of the members to provide a R&D response on the appropriate form and substance to the needs of socio-economic actors in the lymphoma field.

In October 2015, a new major step was taken by the institute with the ISO 9001v2008 certification of activities related to its collection of lymphoma viable cells (CeVi).

This year, their renewal is accompanied by a changeover to the 2015 version. This means a better understanding of leadership, a more risk and opportunity-driven approach, a better control of institute’s stakeholders and a better management of major changes such as the arrival of new members.

 

10 October 2017
6 October 2017

Making the Institut Curie a reference for Technology Transfer in oncology

Paris, September 25th, 2017 - The Institut Curie (Curie Cancer Carnot Institute) has adopted an ambitious strategy for technology transfer and partnerships with innovative companies. This new dynamic, initiated within the framework of the 2015-2020 MC21 strategic plan, aims at positioning the Institut Curie a reference for technology transfer in oncology. Faithful to the model conceived by Marie Curie in 1909, this new breath will strengthen the interactions between research and care, catalyzing the transformation of research findings into medical applications for maximum patient benefit.

Read the press release

21 July 2017

Scalinx: Electronics, from one world to another

The product of research carried out by its founder, Hussein Fakhoury, at the Télécom ParisTech laboratories (part of the Télécom & Société Numérique Carnot Institute), Scalinx is destined to shine as a French gem in the field of electronics. By developing a new generation of analog-to-digital converters, this startup is attracting the attention of stakeholders in strategic fields such as the defense and space sectors. These components are found in all electronic systems that interface analog and digital functions, whose performance depends on the quality of the converters they use.

More information about the success story

Pages